Alendronate induced subacute cutaneous lupus erythematosus successfully treated with intravenous immunoglobulin

Uzuncakmak T. K., Bayazit S., Askin O., Engin B., Ugurlu S., Sar M., ...Daha Fazla

DERMATOLOGIC THERAPY, cilt.33, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/dth.14477
  • Dergi Adı: DERMATOLOGIC THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • İstanbul Üniversitesi Adresli: Evet

Özet

The subacute cutaneous lupus erythematosus (SCLE) is a distinct subtype of lupus erythematosus (LE) representing specific clinical and serological features. Almost 20%-30% of the cases with SCLE are predicted to associated with medications. Thiazide diuretics, terbinafine, antiepileptic, and proton pump inhibitors are the best-known drugs to induce drug-related SCLE. Herein we want to present a 65-year-old female with alendronate induced SCLE, resistant to classical therapies, and respond well to intravenous immunoglobulin (IVIG), suggesting that IVIG could be an alternative treatment in patients resistant to classical treatment protocols.